Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
The phase III MONARCH randomized controlled trial (NCT02332590) demonstrated that in patients with rheumatoid arthritis (RA), sarilumab (anti-interleukin-6 receptor monoclonal antibody) monotherapy is superior...
Source: Arthritis Research and Therapy - Category: Rheumatology Authors: Vibeke Strand, Laure Gossec, Clare W. J. Proudfoot, Chieh-I Chen, Matthew Reaney, Sophie Guillonneau, Toshio Kimura, Janet van Adelsberg, Yong Lin, Erin K. Mangan, Hubert van Hoogstraten and Gerd R. Burmester Tags: Research article Source Type: research